Header Logo

Connection

CHRISTIE BALLANTYNE to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Cardiovascular Diseases.
CHRISTIE BALLANTYNE
Connection Strength
21.032
Cardiovascular Diseases
  1. Intensive Lifestyle Intervention, Cardiac?Biomarkers, and Cardiovascular?Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study. J Am Coll Cardiol. 2025 Feb 11; 85(5):489-500.
    View in: PubMed
    Score: 0.401
  2. HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize? N Engl J Med. 2024 May 02; 390(17):1622-1623.
    View in: PubMed
    Score: 0.384
  3. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun; 18(3):e308-e319.
    View in: PubMed
    Score: 0.384
  4. Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults. JAMA Netw Open. 2024 01 02; 7(1):e2351927.
    View in: PubMed
    Score: 0.378
  5. The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour. Tex Heart Inst J. 2023 11 17; 50(6).
    View in: PubMed
    Score: 0.374
  6. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023 11 09; 30(16):1731-1740.
    View in: PubMed
    Score: 0.374
  7. Lipid-Lowering Therapy in the Elderly: Are Current Guidelines a Sign of Ageism in Medical Care? J Am Coll Cardiol. 2023 04 11; 81(14):1350-1352.
    View in: PubMed
    Score: 0.359
  8. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2023 Mar-Apr; 17(2):208-218.
    View in: PubMed
    Score: 0.356
  9. Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project. Atherosclerosis. 2023 02; 367:15-23.
    View in: PubMed
    Score: 0.353
  10. Clonal hematopoiesis of indeterminate potential and cardiovascular disease. Transl Res. 2023 05; 255:152-158.
    View in: PubMed
    Score: 0.344
  11. Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis. 2022 05; 349:110-122.
    View in: PubMed
    Score: 0.336
  12. Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
    View in: PubMed
    Score: 0.336
  13. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022 07 01; 174:1-11.
    View in: PubMed
    Score: 0.336
  14. PCSK9-targeted therapies: present and future approaches. Nat Rev Cardiol. 2021 12; 18(12):805-806.
    View in: PubMed
    Score: 0.327
  15. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Curr Cardiol Rep. 2021 07 16; 23(9):116.
    View in: PubMed
    Score: 0.318
  16. Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):114-121.
    View in: PubMed
    Score: 0.312
  17. How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management? Curr Atheroscler Rep. 2021 04 01; 23(6):28.
    View in: PubMed
    Score: 0.312
  18. Prevention: The past, present, and future of medicine and society. J Clin Lipidol. 2021 Mar-Apr; 15(2):245-247.
    View in: PubMed
    Score: 0.307
  19. Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. J Clin Endocrinol Metab. 2020 12 01; 105(12).
    View in: PubMed
    Score: 0.305
  20. New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. Annu Rev Med. 2021 01 27; 72:431-446.
    View in: PubMed
    Score: 0.304
  21. Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. J Am Heart Assoc. 2020 07 07; 9(13):e015405.
    View in: PubMed
    Score: 0.296
  22. Dietary and Pharmacological Fatty Acids and Cardiovascular Health. J Clin Endocrinol Metab. 2020 04 01; 105(4).
    View in: PubMed
    Score: 0.291
  23. "Zero": The New Superhero or Superhero in Training? J Am Coll Cardiol. 2019 11 05; 74(18):2331.
    View in: PubMed
    Score: 0.283
  24. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 04; 27(6):593-603.
    View in: PubMed
    Score: 0.278
  25. Seven Metrics That Will Determine Your Cardiovascular Success or Failure. JACC Heart Fail. 2019 08; 7(8):648-650.
    View in: PubMed
    Score: 0.277
  26. Statin use in carnitine palmitoyltransferase II deficiency. J Clin Lipidol. 2019 Jul - Aug; 13(4):550-553.
    View in: PubMed
    Score: 0.274
  27. Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
    View in: PubMed
    Score: 0.267
  28. Low-Density Lipoprotein Cholesterol: Is 160 the New 190? Circulation. 2018 11 20; 138(21):2326-2329.
    View in: PubMed
    Score: 0.265
  29. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 01 03; 380(1):11-22.
    View in: PubMed
    Score: 0.264
  30. Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism. J Thromb Haemost. 2018 10; 16(10):1964-1972.
    View in: PubMed
    Score: 0.260
  31. Short-Term Global Cardiovascular Disease Risk?Prediction in Older Adults. J Am Coll Cardiol. 2018 06 05; 71(22):2527-2536.
    View in: PubMed
    Score: 0.252
  32. Bempedoic Acid (ETC-1002): A Current Review. Cardiol Clin. 2018 May; 36(2):257-264.
    View in: PubMed
    Score: 0.251
  33. Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Curr Cardiol Rep. 2017 03; 19(3):19.
    View in: PubMed
    Score: 0.235
  34. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 10; 253:81-87.
    View in: PubMed
    Score: 0.227
  35. Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. Am J Cardiol. 2015 Aug 01; 116(3):481-4.
    View in: PubMed
    Score: 0.207
  36. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014 Oct; 11(10):563-75.
    View in: PubMed
    Score: 0.195
  37. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013 Jul; 44(7):1803-8.
    View in: PubMed
    Score: 0.180
  38. Ultrasound in cardiovascular risk prediction: don't forget the plaque! J Am Heart Assoc. 2013 Apr 18; 2(2):e000180.
    View in: PubMed
    Score: 0.180
  39. Authors' reply. Am J Cardiol. 2013 Feb 01; 111(3):455-6.
    View in: PubMed
    Score: 0.177
  40. Developing and assessing cardiovascular biomarkers. Transl Res. 2012 Apr; 159(4):265-76.
    View in: PubMed
    Score: 0.165
  41. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
    View in: PubMed
    Score: 0.163
  42. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol. 2011 May; 8(5):253-65.
    View in: PubMed
    Score: 0.155
  43. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
    View in: PubMed
    Score: 0.143
  44. Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends? Crit Pathw Cardiol. 2007 Jun; 6(2):41-5.
    View in: PubMed
    Score: 0.120
  45. Lipids and CVD management: towards a global consensus. Eur Heart J. 2005 Nov; 26(21):2224-31.
    View in: PubMed
    Score: 0.104
  46. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
    View in: PubMed
    Score: 0.102
  47. Mid-life anti-inflammatory metabolites are inversely associated with long-term cardiovascular disease events. EBioMedicine. 2025 Feb; 112:105551.
    View in: PubMed
    Score: 0.101
  48. Trends in Cardiovascular Disease-Related Mortality in Texas. Tex Heart Inst J. 2024 Jul-Dec; 51(2):e248426.
    View in: PubMed
    Score: 0.101
  49. Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk. BMC Med Genomics. 2024 10 24; 17(1):255.
    View in: PubMed
    Score: 0.100
  50. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024 Sep-Oct; 18(5):e647-e663.
    View in: PubMed
    Score: 0.099
  51. Comparing Cardiovascular Risk Classification of U.S. Adults According to Pooled Cohort Equations and PREVENT Equations: Cross-Sectional Analysis of the National Health and Nutrition Examination Survey. Ann Intern Med. 2024 Oct; 177(10):1444-1448.
    View in: PubMed
    Score: 0.099
  52. Global burden of cardiovascular disease attributable to smoking, 1990-2019: an analysis of the 2019 Global Burden of Disease Study. Eur J Prev Cardiol. 2024 Jul 23; 31(9):1123-1131.
    View in: PubMed
    Score: 0.098
  53. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024 06 11; 331(22):1898-1909.
    View in: PubMed
    Score: 0.097
  54. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort. J Am Coll Cardiol. 2024 Apr 23; 83(16):1511-1525.
    View in: PubMed
    Score: 0.096
  55. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. Eur Heart J. 2024 Apr 01; 45(13):1173-1176.
    View in: PubMed
    Score: 0.096
  56. Oral PCSK9 Inhibitors. Curr Atheroscler Rep. 2024 05; 26(5):147-152.
    View in: PubMed
    Score: 0.096
  57. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024 Apr 23; 83(16):1529-1539.
    View in: PubMed
    Score: 0.096
  58. Intensive Blood Pressure Lowering in Individuals With Low Diastolic Blood Pressure and Elevated Troponin Levels in SPRINT. J Am Heart Assoc. 2024 Mar 19; 13(6):e032493.
    View in: PubMed
    Score: 0.096
  59. Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol. JAMA Cardiol. 2024 Mar 01; 9(3):263-271.
    View in: PubMed
    Score: 0.095
  60. Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases. J Natl Med Assoc. 2024 Jun; 116(3):258-270.
    View in: PubMed
    Score: 0.095
  61. Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024 02 06; 83(5):562-573.
    View in: PubMed
    Score: 0.095
  62. Social Vulnerability and Cardiovascular-Related Mortality Among Older Adults in the United States. Am J Med. 2024 02; 137(2):122-127.e1.
    View in: PubMed
    Score: 0.093
  63. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023 10 05; 389(14):1273-1285.
    View in: PubMed
    Score: 0.092
  64. Age-Related Differences in the Contribution of Systolic Blood Pressure and Biomarkers to Cardiovascular Disease Risk Prediction: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Cardiol. 2023 10 01; 204:295-301.
    View in: PubMed
    Score: 0.092
  65. Coronary heart disease and ischemic stroke polygenic risk scores and atherosclerotic cardiovascular disease in a diverse, population-based cohort study. PLoS One. 2023; 18(6):e0285259.
    View in: PubMed
    Score: 0.091
  66. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.090
  67. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. J Am Heart Assoc. 2023 05 02; 12(9):e029175.
    View in: PubMed
    Score: 0.090
  68. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023 06; 25(6):1750-1757.
    View in: PubMed
    Score: 0.089
  69. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2023 05 02; 147(18):1411-1413.
    View in: PubMed
    Score: 0.089
  70. Reply: Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia. J Clin Lipidol. 2023 Mar-Apr; 17(2):304-305.
    View in: PubMed
    Score: 0.089
  71. A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study. J Proteomics. 2023 02 10; 272:104788.
    View in: PubMed
    Score: 0.088
  72. Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia. J Clin Lipidol. 2023 Jan-Feb; 17(1):150-156.
    View in: PubMed
    Score: 0.087
  73. Patient and Clinician Perceptions of Precision Cardiology Care: Findings From the HeartCare Study. Circ Genom Precis Med. 2022 12; 15(6):e003605.
    View in: PubMed
    Score: 0.087
  74. Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 12 01; 184:7-13.
    View in: PubMed
    Score: 0.087
  75. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022 Dec; 45(12):1303-1310.
    View in: PubMed
    Score: 0.086
  76. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
    View in: PubMed
    Score: 0.086
  77. Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis. Prog Cardiovasc Dis. 2022 Sep-Oct; 74:19-27.
    View in: PubMed
    Score: 0.086
  78. PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vasc Health Risk Manag. 2022; 18:555-566.
    View in: PubMed
    Score: 0.085
  79. Guideline-Concordant Statin Therapy Use?in Secondary Prevention: Should the Medical Community Wait for Divine Intervention? J Am Coll Cardiol. 2022 05 10; 79(18):1814-1817.
    View in: PubMed
    Score: 0.084
  80. Lipoprotein(a) and ethnicities. Atherosclerosis. 2022 05; 349:42-52.
    View in: PubMed
    Score: 0.084
  81. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 04 06; 43(14):1401-1412.
    View in: PubMed
    Score: 0.084
  82. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc. 2022 04 05; 11(7):e024999.
    View in: PubMed
    Score: 0.084
  83. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.083
  84. Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation. 2022 01 25; 145(4):259-267.
    View in: PubMed
    Score: 0.082
  85. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.082
  86. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med. 2022 05; 135(5):603-606.
    View in: PubMed
    Score: 0.082
  87. The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community. J Am Coll Cardiol. 2021 11 16; 78(20):2019-2021.
    View in: PubMed
    Score: 0.081
  88. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021 11 07; 42(42):4324-4332.
    View in: PubMed
    Score: 0.081
  89. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021 11 30; 144(22):1750-1759.
    View in: PubMed
    Score: 0.081
  90. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.081
  91. Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007485.
    View in: PubMed
    Score: 0.080
  92. Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021 09 07; 10(17):e020890.
    View in: PubMed
    Score: 0.080
  93. Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genet Med. 2021 12; 23(12):2404-2414.
    View in: PubMed
    Score: 0.080
  94. JCL Roundtable. Making prevention a priority. J Clin Lipidol. 2021 Jul-Aug; 15(4):530-537.
    View in: PubMed
    Score: 0.079
  95. Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
    View in: PubMed
    Score: 0.079
  96. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. 2021 05 07; 42(18):1742-1756.
    View in: PubMed
    Score: 0.079
  97. High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2021 07; 44(7):1657-1663.
    View in: PubMed
    Score: 0.078
  98. Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. Am J Med. 2021 08; 134(8):1047-1051.e2.
    View in: PubMed
    Score: 0.078
  99. Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart. 2021 04; 107(8):650-656.
    View in: PubMed
    Score: 0.077
  100. Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. J Am Coll Cardiol. 2021 02 09; 77(5):559-571.
    View in: PubMed
    Score: 0.077
  101. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System. Cardiovasc Drugs Ther. 2022 04; 36(2):295-300.
    View in: PubMed
    Score: 0.077
  102. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
    View in: PubMed
    Score: 0.077
  103. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
    View in: PubMed
    Score: 0.076
  104. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Circulation. 2021 01 05; 143(1):33-44.
    View in: PubMed
    Score: 0.076
  105. High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. J Am Geriatr Soc. 2021 04; 69(4):986-994.
    View in: PubMed
    Score: 0.076
  106. High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. Diabetes Care. 2020 10; 43(10):e144-e146.
    View in: PubMed
    Score: 0.075
  107. Combining Biomarkers and Imaging for Short-Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. J Am Heart Assoc. 2020 08 04; 9(15):e015410.
    View in: PubMed
    Score: 0.074
  108. The Use of Sex-Specific Factors in the Assessment of Women's Cardiovascular Risk. Circulation. 2020 02 18; 141(7):592-599.
    View in: PubMed
    Score: 0.072
  109. Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. Am J Cardiovasc Drugs. 2020 Feb; 20(1):1-9.
    View in: PubMed
    Score: 0.072
  110. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA. 2020 Jan 28; 323(4):329-338.
    View in: PubMed
    Score: 0.072
  111. JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. J Clin Lipidol. 2020 Jan - Feb; 14(1):4-15.
    View in: PubMed
    Score: 0.072
  112. Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2019 12 31; 188(12):2146-2155.
    View in: PubMed
    Score: 0.072
  113. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 10 15; 74(15):1926-1942.
    View in: PubMed
    Score: 0.070
  114. Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2019 09; 67(9):1795-1802.
    View in: PubMed
    Score: 0.069
  115. Sleep apnea and galectin-3: possible sex-specific relationship. Sleep Breath. 2019 Dec; 23(4):1107-1114.
    View in: PubMed
    Score: 0.067
  116. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.067
  117. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2019 03; 282:52-56.
    View in: PubMed
    Score: 0.067
  118. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 10 07; 39(38):3499-3507.
    View in: PubMed
    Score: 0.066
  119. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
    View in: PubMed
    Score: 0.066
  120. Are All Benefits and Harms Equal? J Am Coll Cardiol. 2018 08 14; 72(7):819-820.
    View in: PubMed
    Score: 0.065
  121. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
    View in: PubMed
    Score: 0.065
  122. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.064
  123. Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions. Curr Atheroscler Rep. 2018 05 21; 20(7):35.
    View in: PubMed
    Score: 0.064
  124. Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
    View in: PubMed
    Score: 0.061
  125. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 04 01; 2(4):361-369.
    View in: PubMed
    Score: 0.059
  126. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. Circulation. 2017 05 30; 135(22):2119-2132.
    View in: PubMed
    Score: 0.059
  127. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar; 40(3):138-148.
    View in: PubMed
    Score: 0.059
  128. Practice-Level Variation in?Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. J Am Coll Cardiol. 2016 09 20; 68(12):1368-9.
    View in: PubMed
    Score: 0.057
  129. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016 10; 4(10):840-9.
    View in: PubMed
    Score: 0.057
  130. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. Am Heart J. 2016 Nov; 181:74-82.
    View in: PubMed
    Score: 0.057
  131. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
    View in: PubMed
    Score: 0.057
  132. Obesity and Subtypes of Incident Cardiovascular Disease. J Am Heart Assoc. 2016 07 28; 5(8).
    View in: PubMed
    Score: 0.056
  133. The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2016 09; 23(14):1529-36.
    View in: PubMed
    Score: 0.055
  134. Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. J Am Coll Cardiol. 2015 Oct 20; 66(16):1803-1812.
    View in: PubMed
    Score: 0.053
  135. Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation. 2015 Nov 24; 132(21):1979-89.
    View in: PubMed
    Score: 0.053
  136. Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis. 2015 Aug; 241(2):641-8.
    View in: PubMed
    Score: 0.052
  137. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J. 2015 Aug; 170(2):380-9.
    View in: PubMed
    Score: 0.052
  138. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
    View in: PubMed
    Score: 0.051
  139. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
    View in: PubMed
    Score: 0.051
  140. Reply: Frequency of inappropriate and nonrecommended prasugrel prescription: great variations. J Am Coll Cardiol. 2014 Dec 09; 64(22):2434-5.
    View in: PubMed
    Score: 0.050
  141. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2015 Jan; 65(1):78-84.
    View in: PubMed
    Score: 0.050
  142. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015 Jan 01; 115(1):21-6.
    View in: PubMed
    Score: 0.050
  143. Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. PLoS One. 2014; 9(9):e107340.
    View in: PubMed
    Score: 0.049
  144. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014 Aug; 34(8):1770-7.
    View in: PubMed
    Score: 0.049
  145. Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014 Jul 01; 63(25 Pt A):2876-7.
    View in: PubMed
    Score: 0.048
  146. The editor's roundtable: hypertriglyceridemia. Am J Cardiol. 2013 Oct 15; 112(8):1133-41.
    View in: PubMed
    Score: 0.046
  147. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013 Jun; 62(6):2116-21.
    View in: PubMed
    Score: 0.044
  148. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol. 2013 Mar; 8(3):434-42.
    View in: PubMed
    Score: 0.044
  149. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann Epidemiol. 2013 Feb; 23(2):66-73.
    View in: PubMed
    Score: 0.044
  150. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012 May; 59(5):653-62.
    View in: PubMed
    Score: 0.041
  151. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011 Sep-Oct; 5(5):338-67.
    View in: PubMed
    Score: 0.040
  152. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011 Oct; 162(4):725-732.e1.
    View in: PubMed
    Score: 0.040
  153. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 May 24; 123(20):2292-333.
    View in: PubMed
    Score: 0.039
  154. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011 Feb 22; 123(7):731-8.
    View in: PubMed
    Score: 0.039
  155. Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol. 2010 May; 30(5):1034-42.
    View in: PubMed
    Score: 0.036
  156. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2009 Sep 29; 54(14):1336-63.
    View in: PubMed
    Score: 0.035
  157. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. Circulation. 2009 Sep 29; 120(13):e100-26.
    View in: PubMed
    Score: 0.035
  158. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009 May 05; 119(17):2408-16.
    View in: PubMed
    Score: 0.034
  159. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009 Feb; 55(2):378-84.
    View in: PubMed
    Score: 0.033
  160. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27.
    View in: PubMed
    Score: 0.032
  161. Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study. Am J Hypertens. 2008 May; 21(5):533-8.
    View in: PubMed
    Score: 0.031
  162. An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5.
    View in: PubMed
    Score: 0.030
  163. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007 Mar 01; 99(5):673-80.
    View in: PubMed
    Score: 0.029
  164. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem. 2005 Jul; 51(7):1102-9.
    View in: PubMed
    Score: 0.026
  165. Associations of Ambulatory Blood Pressure Measurements With High-Sensitivity Troponin and Natriuretic Peptide Levels in SPRINT. Am J Hypertens. 2024 07 15; 37(8):571-579.
    View in: PubMed
    Score: 0.024
  166. Individual and Joint Associations of High-Sensitivity Troponin I and High-Sensitivity Troponin T with Cardiac Phenotypes and Outcomes in the General Population: An Analysis From the Dallas Heart Study. J Am Heart Assoc. 2024 Jul 02; 13(13):e034549.
    View in: PubMed
    Score: 0.024
  167. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol. 2022 01 18; 79(2):220-222.
    View in: PubMed
    Score: 0.021
  168. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
    View in: PubMed
    Score: 0.019
  169. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.018
  170. Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019 08 13; 140(7):618-620.
    View in: PubMed
    Score: 0.017
  171. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. J Womens Health (Larchmt). 2018 09; 27(9):1170-1176.
    View in: PubMed
    Score: 0.016
  172. Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 05 01; 121(9):1056-1064.
    View in: PubMed
    Score: 0.016
  173. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH? patient registry. Atherosclerosis. 2017 Dec; 267:19-26.
    View in: PubMed
    Score: 0.015
  174. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
    View in: PubMed
    Score: 0.015
  175. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8).
    View in: PubMed
    Score: 0.015
  176. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 01 10; 6(1).
    View in: PubMed
    Score: 0.015
  177. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis. 2016 Mar; 246:115-20.
    View in: PubMed
    Score: 0.014
  178. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications. 2015 Mar; 29(2):180-5.
    View in: PubMed
    Score: 0.013
  179. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013 May; 21(5):944-50.
    View in: PubMed
    Score: 0.011
  180. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99.
    View in: PubMed
    Score: 0.011
  181. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res. 2009 Aug; 50(8):1685-91.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.